ASH Educational Highlights: Focus on Immunotherapy

ash18 Site banner 1

The many new ways of immunotherapy in hematological malignancies, from bispecifics, trispecifics, and conjugated monoclonal antibodies to CAR-T cell therapy, were under the spotlight at the last ASH meeting (held virtually from December 5 - 8, 2020).

We've selected a series of educational papers from the ASH Educational Program, covering different aspects of immunology and immunotherapy in lymphomas, leukemias and myeloma. Browse them by clicking on the links below.

Future of CAR T cells in multiple myeloma

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):272-279.

Immunotherapy with cells

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):590-597.

CAR T cells vs allogeneic HSCT for poor-risk ALL

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):501-507.

Practical aspects of building a new immunotherapy program: the future of cell therapy

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):579-584.

CAR T cells for other pediatric non-B-cell hematologic malignancies

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):494-500.

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):487-493.

Fundamentals of immunology for understanding immunotherapy for lymphoma

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):585-589.

Immunotherapy with drugs

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):598-605.

Bispecifics, trispecifics, and other novel immune treatments in myeloma

Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):264-271.

Last Updated on Wednesday 16 December 2020.